Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(12):1591–1598. doi: 10.1054/bjoc.2001.1835

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome

G Somlo 1, J H Doroshow 1, T Synold 1, J Longmate 1, D Reardon 1, W Chow 1, S J Forman 1, L A Leong 1, K A Margolin 1, R J Morgan Jr 1, J W Raschko 1, S I Shibata 1, M L Tetef 1, Y Yen 1, N Kogut 3, J Schriber 2, J Alvarnas 2
PMCID: PMC2363687  PMID: 11401310

Abstract

We assessed the feasibility and pharmacokinetics of high-dose infusional paclitaxel in combination with doxorubicin, cyclophosphamide, and peripheral blood progenitor cell rescue. Between October 1995 and June 1998, 63 patients with high-risk primary [stage II with ≥ 10 axillary nodes involved, stage IIIA or stage IIIB inflammatory carcinoma (n = 53)] or with stage IV responsive breast cancer (n = 10) received paclitaxel 150–775 mg/m2infused over 24 hours, doxorubicin 165 mg/m2as a continuous infusion over 96 hours, and cyclophosphamide 100 mg kg–1. There were no treatment-related deaths. Dose-limiting toxicity was reversible, predominantly sensory neuropathy following administration of paclitaxel at the 775 mg/m2dose level. Paclitaxel pharmacokinetics were non-linear at higher dose levels; higher paclitaxel dose level, AUC, and peak concentrations were associated with increased incidence of paraesthesias. No correlation between stomatitis, haematopoietic toxicities, and paclitaxel dose or pharmacokinetics was found. Kaplan–Meier estimates of 30-month event-free and overall survival for patients with primary breast carcinoma are 65% (95% CI; 51–83%) and 77% (95% CI; 64–93%). Paclitaxel up to 725 mg/m2infused over 24 hours in combination with with doxorubicin 165 mg/m2and cyclophosphamide 100 mg kg–1is tolerable. A randomized study testing this regimen against high-dose carboplatin, thiotepa and cyclophosphamide (STAMP V) is currently ongoing. © 2001 Cancer Research Campaign http://www.bjcancer.com

Full Text

The Full Text of this article is available as a PDF (95.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K. H., Rowlings P. A., Vaughan W. P., Pelz C. J., Fay J. W., Fields K. K., Freytes C. O., Gale R. P., Hillner B. E., Holland H. K. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997 May;15(5):1870–1879. doi: 10.1200/JCO.1997.15.5.1870. [DOI] [PubMed] [Google Scholar]
  2. Bronchud M. H., Howell A., Crowther D., Hopwood P., Souza L., Dexter T. M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989 Jul;60(1):121–125. doi: 10.1038/bjc.1989.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown T., Havlin K., Weiss G., Cagnola J., Koeller J., Kuhn J., Rizzo J., Craig J., Phillips J., Von Hoff D. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 1991 Jul;9(7):1261–1267. doi: 10.1200/JCO.1991.9.7.1261. [DOI] [PubMed] [Google Scholar]
  4. Gianni L., Kearns C. M., Giani A., Capri G., Viganó L., Lacatelli A., Bonadonna G., Egorin M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995 Jan;13(1):180–190. doi: 10.1200/JCO.1995.13.1.180. [DOI] [PubMed] [Google Scholar]
  5. Gianni L., Viganò L., Locatelli A., Capri G., Giani A., Tarenzi E., Bonadonna G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997 May;15(5):1906–1915. doi: 10.1200/JCO.1997.15.5.1906. [DOI] [PubMed] [Google Scholar]
  6. Glück S., Germond C., Lopez P., Cano P., Dorreen M., Koski T., Arnold A., Dulude H., Gallant G. A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. Eur J Cancer. 1998 Jun;34(7):1008–1014. doi: 10.1016/s0959-8049(97)10168-x. [DOI] [PubMed] [Google Scholar]
  7. Greinix H. T., Linkesch W., Seifert M., Kubista E., Czerwenka K., Elahi F., Zielinski C., Hoecker P., Steger G., Schulenburg A. Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients. Acta Oncol. 2000;39(1):47–52. doi: 10.1080/028418600430969. [DOI] [PubMed] [Google Scholar]
  8. Holmes F. A., Walters R. S., Theriault R. L., Forman A. D., Newton L. K., Raber M. N., Buzdar A. U., Frye D. K., Hortobagyi G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797–1805. doi: 10.1093/jnci/83.24.1797-a. [DOI] [PubMed] [Google Scholar]
  9. Hortobagyi G. N., Buzdar A. U., Theriault R. L., Valero V., Frye D., Booser D. J., Holmes F. A., Giralt S., Khouri I., Andersson B. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 2;92(3):225–233. doi: 10.1093/jnci/92.3.225. [DOI] [PubMed] [Google Scholar]
  10. Lotz J. P., Curé H., Janvier M., Morvan F., Legros M., Asselain B., Guillemot M., Roché H., Gisselbrecht C. Intensification thérapeutique et autogreffe de cellules souches hématopoïtiques (CSH) dans le traitement des cancers du sein métastatiques: résultats du programme national Pegase 04. Hematol Cell Ther. 1999 Apr;41(2):71–74. doi: 10.1007/s00282-999-0071-1. [DOI] [PubMed] [Google Scholar]
  11. McCloskey D. E., Kaufmann S. H., Prestigiacomo L. J., Davidson N. E. Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. Clin Cancer Res. 1996 May;2(5):847–854. [PubMed] [Google Scholar]
  12. O'Shaughnessy J. A., Fisherman J. S., Cowan K. H. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol. 1994 Oct;21(5 Suppl 8):19–23. [PubMed] [Google Scholar]
  13. Peters W. P., Ross M., Vredenburgh J. J., Meisenberg B., Marks L. B., Winer E., Kurtzberg J., Bast R. C., Jr, Jones R., Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun;11(6):1132–1143. doi: 10.1200/JCO.1993.11.6.1132. [DOI] [PubMed] [Google Scholar]
  14. Reichman B. S., Seidman A. D., Crown J. P., Heelan R., Hakes T. B., Lebwohl D. E., Gilewski T. A., Surbone A., Currie V., Hudis C. A. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1993 Oct;11(10):1943–1951. doi: 10.1200/JCO.1993.11.10.1943. [DOI] [PubMed] [Google Scholar]
  15. Riley C. A., Crom W. R., Evans W. E. Loop-column extraction and liquid chromatographic analysis of doxorubicin and three metabolites in plasma. Ther Drug Monit. 1985;7(4):455–460. doi: 10.1097/00007691-198512000-00017. [DOI] [PubMed] [Google Scholar]
  16. Rizzo J., Riley C., von Hoff D., Kuhn J., Phillips J., Brown T. Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. J Pharm Biomed Anal. 1990;8(2):159–164. doi: 10.1016/0731-7085(90)80023-i. [DOI] [PubMed] [Google Scholar]
  17. Rodenhuis S., Richel D. J., van der Wall E., Schornagel J. H., Baars J. W., Koning C. C., Peterse J. L., Borger J. H., Nooijen W. J., Bakx R. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998 Aug 15;352(9127):515–521. doi: 10.1016/S0140-6736(98)01350-6. [DOI] [PubMed] [Google Scholar]
  18. Somlo G., Doroshow J. H., Forman S. J., Leong L. A., Margolin K. A., Morgan R. J., Jr, Raschko J. W., Akman S. A., Ahn C., Nagasawa S. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. Cancer. 1994 Mar 15;73(6):1678–1685. doi: 10.1002/1097-0142(19940315)73:6<1678::aid-cncr2820730621>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  19. Somlo G., Doroshow J. H., Forman S. J., Odom-Maryon T., Lee J., Chow W., Hamasaki V., Leong L., Morgan R., Jr, Margolin K. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol. 1997 Aug;15(8):2882–2893. doi: 10.1200/JCO.1997.15.8.2882. [DOI] [PubMed] [Google Scholar]
  20. Somlo G., Sniecinski I., Odom-Maryon T., Nowicki B., Chow W., Hamasaki V., Leong L., Margolin K., Morgan R., Jr, Raschko J. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Blood. 1997 Mar 1;89(5):1521–1528. [PubMed] [Google Scholar]
  21. Sonnichsen D. S., Hurwitz C. A., Pratt C. B., Shuster J. J., Relling M. V. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994 Mar;12(3):532–538. doi: 10.1200/JCO.1994.12.3.532. [DOI] [PubMed] [Google Scholar]
  22. Stadtmauer E. A., O'Neill A., Goldstein L. J., Crilley P. A., Mangan K. F., Ingle J. N., Brodsky I., Martino S., Lazarus H. M., Erban J. K. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000 Apr 13;342(15):1069–1076. doi: 10.1056/NEJM200004133421501. [DOI] [PubMed] [Google Scholar]
  23. Stemmer S. M., Cagnoni P. J., Shpall E. J., Bearman S. I., Matthes S., Dufton C., Day T., Taffs S., Hami L., Martinez C. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol. 1996 May;14(5):1463–1472. doi: 10.1200/JCO.1996.14.5.1463. [DOI] [PubMed] [Google Scholar]
  24. Synold T. W., Doroshow J. H. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion. J Infus Chemother. 1996 Spring;6(2):69–73. [PubMed] [Google Scholar]
  25. Vahdat L. T., Papadopoulos K., Balmaceda C., McGovern T., Dunleavy J., Kaufman E., Fung B., Garrett T., Savage D., Tiersten A. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Res. 1998 Jul;4(7):1689–1695. [PubMed] [Google Scholar]
  26. Williams S. F., Mick R., Desser R., Golick J., Beschorner J., Bitran J. D. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol. 1989 Dec;7(12):1824–1830. doi: 10.1200/JCO.1989.7.12.1824. [DOI] [PubMed] [Google Scholar]
  27. Wilson W. H., Berg S. L., Bryant G., Wittes R. E., Bates S., Fojo A., Steinberg S. M., Goldspiel B. R., Herdt J., O'Shaughnessy J. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994 Aug;12(8):1621–1629. doi: 10.1200/JCO.1994.12.8.1621. [DOI] [PubMed] [Google Scholar]
  28. Wood W. C., Budman D. R., Korzun A. H., Cooper M. R., Younger J., Hart R. D., Moore A., Ellerton J. A., Norton L., Ferree C. R. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994 May 5;330(18):1253–1259. doi: 10.1056/NEJM199405053301801. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES